Tag Archives: Digital Health

Hot Investor Mandate 2: USA Venture Fund Invests in Therapeutics and Digital Health, With Strong Interests in Small Molecule Therapies in Inflammation, Infectious, Autoimmune Diseases

31 May

A USA-based venture capital fund is currently making investments out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-3 million range. The firm is looking to make equity investments and is open to investing in companies globally.

The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools.

The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , , ,

Hot Investor Mandate 1: Japanese CVC with USA Offices Invests in Novel Pharmaceutical, Medical Device, and Digital Health Technologies

24 May

A corporate venture arm of a diversified business based in Tokyo is focused on investing in various sectors, including healthcare. The team is based in offices in both the West and East Coast. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Hot Investor Mandate 4: VC Firm with Offices in New England Seeks Digital Health Platform Companies Relating to Drug Discovery, Delivery, and Manufacturing

24 May

A venture capital firm with offices in the New England region currently manages four funds, two of which are dedicated to sector specific investments. The first focuses on healthcare and life science investments, while the other is focused on investing in built environment technology. On average, the initial size of investment is up to $1M, and the firm has the capacity to invest $2-4 M after the initial investment. The firm initially invests from Seed to Series A typically, but has come in at later stage investments. The firm is willing to lead in seed rounds and co-invest in later rounds. The firm has a preference for investing in US, but can invest globally. The firm is actively seeking new investment opportunities.

The firm is a flexible investor that is currently looking for life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies. The firm typically does not invest in therapeutics, medical devices, and diagnostics. The firm prefers enterprise to direct-to-consumer health IT companies. In addition, the firm prefers companies that meet at least $1M revenue traction on the health IT side.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 1: Toronto-Based Single Family Office Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies

3 May

A single family office based in Toronto, Ontario has its main focus on real estate and mining, but is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space. The firm may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 3: USA VC Firm Seeks to Invest in All Sectors of Life Sciences, with Focus on Companies Outside of Major Biotech Hubs

3 May

A venture capital firm based in Texas is focused on early and growth-stage biotech and medical device companies. The group is currently raising their second fund and is actively evaluating deals. Initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm looks to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , ,

Hot Investor Mandate 4: Venture Arm of Large Korean Corporate Invests in Digital Health, with Increased Interests in Investment Opportunities in Biotech Therapeutics

3 May

A venture capital arm of a large Korean corporate has several offices in the USA. The firm has approximately has invested over $200M in 40 companies in the last year and invested $100M in 20 companies in 2016. The investment size greatly varies, depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , ,

Hot Investor Mandate 4: Toronto-Based Global Firm Seeks to Invest Early-Stage Medical Device, Diagnostics, and Digital Health Companies

19 Apr

A firm based in Toronto that has offices worldwide manages a variety of different investment vehicles including private equity and multi-strategy funds. In the life sciences, the firm makes equity investments typically at Series A; initial investments range from $100,000-$1 million with follow on capital available of $1-3 million. The firm focuses on companies based in North America but has the capacity to invest worldwide.

In the life sciences, the firm focuses on medical devices, diagnostics and digital health companies. The firm prefers to invest in companies that are close to commercialization or which are already generating revenue (for example, device companies must ideally be ready to file for a CE Mark, 510k or Health Canada application).

The firm prefers to invest in experienced entrepreneurs who have deep knowledge of their sector. The firm only invests in companies developing products that have a clear path to market, and which serve a clear need; the firm prefers to invest in companies that are no more than a year from obtaining revenues. As the firm has offices globally, the firm is well placed to help portfolio companies make international distribution or license/royalty agreements. The firm invests in both public and privately-held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

← Older Entries
Newer Entries →